165.04
8.39 (5.36%)
| Previous Close | 156.65 |
| Volume | 3,589,128 |
| Price / Earnings (Forward) | 12.25 |
| Price / Sales | 4.30 |
| Price / Book | 5.82 |
| 52 Weeks Range |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
News Mood
- Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
- Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
AIStockmoo Score
| Value 30% | -0.5 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| High debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -4.5 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 2.1 |
| Insider Activity info | NA |
| Institutions net +2.00% of shares in their latest 13F filings: 411 holders increased, 397 decreased (quarter to 30 Sep 2026). info | |
| Short interest -13.8% from 31 Aug to 30 Oct 2026, 1.9 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars partly agree, so the score is unchanged. | |
| Not in score | |
| Price is low against its 52-week average. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is near support. info | |
| Final Score | -1.14 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Alnylam Pharmaceuticals, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ALNY | - | - | - | 5.82 |
| ABVX | - | - | - | 16.72 |
| GMAB | - | - | - | 4.99 |
| REGN | - | 0.39% | - | 2.95 |
| CRSP | - | - | - | 2.48 |
| FOLD | 5 B | - | - | - |
Select this tab to load the latest available analysis.
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 97.56% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 110.40%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 411 | 14,635,522 |
| Decreased | 397 | 12,567,345 |
| New | 98 | 2,122,905 |
| Sold out | 112 | 1,516,561 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 5,465,979 | 1.9 |
| 15 Oct 2026 | 6,568,786 | 5.1 |
| 30 Sep 2026 | 7,711,495 | 6.5 |
| 15 Sep 2026 | 7,194,097 | 4.1 |
| 31 Aug 2026 | 6,340,087 | 3.9 |
| 14 Aug 2026 | 4,770,978 | 2.4 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
What Moved Alnylam Stock?
For questions about this article or underlying research, email [email protected]. |
| 10 Nov 2026 | Yahoo Finance |
Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of… |
| 09 Nov 2026 | Yahoo Finance |
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
CAMBRIDGE, Mass., November 09, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR… |
| 06 Nov 2026 | Yahoo Finance |
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts. |
| 04 Nov 2026 | Yahoo Finance |
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
CAMBRIDGE, Mass., November 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters… |
| 04 Nov 2026 | Yahoo Finance |
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., November 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET)… |
| 03 Nov 2026 | Yahoo Finance |
What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change?
Alnylam Pharmaceuticals (NasdaqGS:ALNY) plans to present five-year HELIOS-B data on AMVUTTRA at major medical meetings in 2026. The company will share long-term efficacy and safety findings from the pivotal HELIOS-B trial at the American Heart Association congress. Alnylam also intends to present… |
| 03 Nov 2026 | Yahoo Finance |
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
CAMBRIDGE, Mass., November 03, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago… |
| 02 Nov 2026 | Yahoo Finance |
Should You Buy The Dip In Alnylam Stock?
For questions about this article or underlying research, email [email protected]. |
| 02 Nov 2026 | Yahoo Finance |
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter. |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |